GSK Seeks High Court Input On IP Safe-Harbor Rule
GlaxoSmithKline PLC asked the U.S. Supreme Court last month to review a decision that upheld Classen Immunotherapies Inc.'s patents for evaluating a vaccine immunization schedule, arguing the Federal Circuit wrongly ruled...To view the full article, register now.
Already a subscriber? Click here to view full article